ArticleJournal of Alzheimer's disease reports
Safety, acceptability, and usability of an immersive gamification technology system for use in patients with behavioral and psychological symptoms of dementia (phase 1 trial).
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05265182 (Developing an Immersive Gamification Technology System), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Developing an Immersive Gamification Technology System (ImGTS) for the Management of Patients With Behavioral and Psychological Symptoms of Dementia (Phase 1 Trial)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Virtual reality (VR) is increasingly explored as a novel non-pharmacologic approach to manage Alzheimer's disease, particularly the behavioral and psychological symptoms of dementia. Objective: This phase 1 study aimed to develop an immersive gamification technology system (ImGTS) for the local context and describe its safety, acceptability, and usability among healthy adults prior to clinical deployment in patients with dementia. Methods: The ImGTS was tested on 30 healthy adults using a head-mounted display (HMD; n = 15) or a semi-cave automatic virtual environment (semi-CAVE; n = 15) across four testing sessions. Both qualitative and quantitative questionnaires were administered, with data analyzed through thematic analysis and descriptive statistics. Measures included sense of place, usability, and safety. Results: Participants in both setups reported low VR sickness incidence (four out of 15 participants for both) with decreasing VR sickness questionnaire (VRSQ) scores across sessions (1.50 ± 3.96 to 0 for HMD and 0.78 ± 1.62 to 0 for semi-CAVE). Only mild, mostly oculomotor/disorientation symptoms and slight, transient general discomfort were observed in a minority of participants, using the HMD and semi-CAVE, respectively. Participants also articulated predominantly positive subjective descriptions, with reports of nostalgia and use of strong affective word choices. All participants completed key tasks with little difficulty. The three main activities received "neutral to positive" satisfaction ratings. Conclusions: Overall, our findings indicate that both the HMD and semi-CAVE setups were safe, acceptable, and usable by healthy adult participants. These foundational results support the implementation of phase 2 trials to establish clinical efficacy and tolerability directly within the target population of older individuals living with dementia. Clinical Trial ID: NCT05265182.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.